Phase I trial of SUVN 502 in male volunteers.
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs SUVN 502 (Primary)
- Indications Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Suven Life Sciences
- 14 Oct 2009 According to a Suven Life Sciences media release, SUVN 502 has shown to be safe at all doses tested with excellent bioavailability and a half life suitable for once-daily treatment.
- 12 Jul 2009 Results have been presented at ICAD 2009.
- 08 Sep 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History